Industry News

Sanuwave Health Reports 2010 Financial Results
  Sanuwave Health Inc (Alpharetta, GA) has reported the financial results for the year ended on December 31, 2010 in addition to reviewing the year’s accomplishments and progress. The company completed its dermaPACE® pivotal Phase III clinical trial to treat diabetic foot ulcers (DFU) and reported safety and efficacy results during the fourth quarter. The company also submitted the first of three modules of their Premarket Approval (PMA) application to the US Food and Drug Administration (FDA), which included preclinical data and the results of prior clinical testing. By completing this rigorous Phase III clinical trial and immediately initiating their modular PMA submission process, the company has surpassed a key milestone for transforming the brand from a development stage entity in to a commercial company. As demonstrated by the notable results from the DFU clinical trial, the product has the potential to help a large number of patients who suffer through the physical and emotional distress of debilitating foot ulcers. Pending FDA approval, the company looks forward to bringing the product to medical professionals and patients alike, while aiming to make a significant impact on wound healing and quality of life.

  Visit www.sanuwave.com for more information.

Derma Sciences Presents Posters and Presentations At 24th Annual SAWC
  Derma Sciences Inc (Princeton, NJ), offered both poster and expert presentations featuring Medihoney® and Xtrasorb® at the Symposium on Advanced Wound Care and Wound Healing Society Meeting (SAWC/WHS), which took place April 14–17, 2011 in Dallas, TX. Use of Active Leptospermum Honey to Heal Pressure Ulcers: A Case Series of Pressure Ulcer Patients by Cynthia Bridgman BSN, RN, CWOCN and Carol Hall BSN, RN, CWOCN, CFCN of The University of Texas Southwestern Medical Center at Dallas and Protease Modification by Super Absorbent Polymer Dressings by Marcy Turkos, PT, DPT, CWS; Kimberly Stallo, BS, RN, CWOCN, of Derma Sciences were the two posters presented that featured both products from the company’s wound care portfolio. The following presentations highlighting the products took place at the company’s booth: The Versatility of Medihoney for Use on a Variety of Stalled Wounds and Wounds of Atypical Etiologies and Medihoney and Xtrasorb, The Value of an Osmotic Gradient on Chronic Wounds: A Combination Therapy.

  Visit www.dermasciences.com for more information.

Leading Health Insurer Announces Coverage of Spiracur’s SNaP Wound Care System
  Spiracur Inc (Sunnyvale, CA), which recently developed an ultraportable and disposable negative pressure wound therapy (NPWT) device, and Highmark Inc (Pittsburgh, PA) a health insurer announced new coverage for Spiracur’s SNaP® Wound Care System and related supplies. The SNaP Wound Care System (Smart Negative Pressure) is changing the approach of how wound healing is delivered to patients. Its inventive design eliminates the electric or battery powered pump used to deliver NPWT. The system is completely silent and lightweight, weighing only 2.2 ounces. As innovation is a top priority at Highmark, the company is providing their customers with creative solutions to meet patient needs. The wound care system is a prime example of such an innovative approach that will greatly benefit Highmark members suffering from diabetes, circulatory problems, and additional conditions. Highmark is an independent licensee of the Blue Cross and Blue Shield Association offering a variety of indemnity and managed care health insurance products, along with consumer-driven health plans and Medicare supplemental products in western Pennsylvania, central Pennsylvania, and the Lehigh Valley.